This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …

Under the auspices of an International Working Group, seven centers submitted diagnostic
and follow-up information on 1545 patients with World Health Organization-defined …

Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a
calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential …

Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by
JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; …

Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at
increased risk for thrombotic events. However, no population-based study has estimated this …

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)
constitute theBCR-ABL1–negative myeloproliferative neoplasms and are characterized by …

Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …

A quarter of patients with essential thrombocythemia or primary myelofibrosis carry a driver
mutation of CALR, the calreticulin gene. A 52-bp deletion (type 1) and a 5-bp insertion (type …

Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by
arterial and venous complications, progression to myelofibrosis, and transformation to acute …